Company Name Pearl Therapeutics
Mailing Address 200 Saginaw Drive Redwood City, CA 94063
Company Description Pearl Therapeutics is focused on developing a pipeline of novel and superior products for chronic respiratory disorders, providing patients with advanced therapeutic options in familiar and well accepted dosage forms. The company has licensed advanced particle technology from Nektar Therapeutics (Nasdaq: NKTR) for developing a series of products in selected therapeutic fields.
Proceeds Purposes Proceeds from this financing will be used by Pearl to start Phase 3 for PT003, Pearl’s lead candidate product comprised of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist (LABA) delivered via a metered dose inhaler (HFA MDI).